Document is current

Any future updates will be listed below

A randomized Bayesian phase I-II dose optimization design for combination cancer therapies with progression-free survival end point

Crossref DOI link: https://doi.org/10.1186/s12874-025-02665-4

Published Online: 2025-09-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark